comprehensive -WSS

comprehensive

author：knowledge 2025-09-03 05:40:32 - browse：2

Photograph of Bill Cassidy. -- health policy coverage from STAT — Sen. Bill Cassidy (R-La.) Kevin Dietsch/Getty Images

WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival approved this week, everyone in Washington is thinking about how to manage the crashing wave of weight loss drug costs.

The explosive national demand for weight management therapies and diabetes drugs like Ozempic — all of which are indicated for indefinite use — has become central in an ongoing policy debate over high drug costs and controversial tactics to manage them, including President Biden’s plan to let the government negotiate directly with pharmaceutical companies. Seventy percent of Americans could qualify for these medicines.

Sen. Bill Cassidy (R-La.), the highest-ranking Republican on the Senate’s health policy committee, has vehemently opposed the negotiation plan, arguing it reduces incentives to develop new therapies and may not actually reduce patients’ costs.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Some top drug companies are starting to take action on climate

WSS

Experts study whether long Covid risk adds up with each reinfection

The Karikó problem: Lessons for funding basic research

Lawsuit highlights wrinkle for disputes over surprise medical bills

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Lawsuit highlights wrinkle for disputes over surprise medical bills

What is microchimerism and how does it affect maternal health?

Wikipedia

comprehensive

Wikipedia

How one medical school became remarkably diverse

The United States is paying nearly triple for new Covid vaccines

The cancer drug shortage isn’t new — and neither are the solutions

The biotech scorecard for Q4: 16 stock

After affirmative action ruling, medical educators look to 'holistic review'

Travis Kelce and the trap of celebrity vaccine endorsements

Medical records are filled with copy

Will an HIV vaccine ever be a reality?

Drug repurposing or repositioning? The language matters

Some top drug companies are starting to take action on climate

focus

How neuroscience research could help beat back brain cancer

Readout LOUD podcast: ESMO highlights & Roivant's big deal

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

Will an HIV vaccine ever be a reality?

After Sarepta trial failure, Duchenne families brace for more debate

2023 Nobel Prize in Medicine goes to Karikó and Weissman

focus

Wikipedia

knowledge

hotspot